Premise: User asked 2026-05-26 "do we have this? did we have quantum at all" after the @thestockwhale 9-name quantum pitch (https://x.com/thestockwhale/status/2059019897024479490). Coverage audit showed we have 3 quantum-tagged names (IONQ/RGTI in ai-scan, IBM in watching) — thin for a ~$100B+ research investment area. Per feedback_prove_dumb_or_validate_no_default_skip.md, the default is to validate the thesis from first principles before filing coverage decisions. This note does that.

The artifact to validate

@thestockwhale (Discord paid-signals shop per reference_thestockwhale_skip.md) — 2026-05-25 21:12 UTC:

"In 2025, I told you to buy quantum and we made millions together. In 2026, I told you to buy quantum AGAIN. This time, you'll retire within the next 4 years. Here are the BEST quantum stocks to buy right now:

1. IonQ $IONQ
2. International Business Machines $IBM
3. Infleqtion $INFQ
4. Rigetti Computing $RGTI
5. D-Wave Quantum $QBTS
6. Xanadu $XNDU
7. Quantum Computing $QUBT
8. Arqit Quantum $ARQQ
9. Horizon Quantum $HQ All my buy and sell signals in Discord @ stockwhale.vip"

Two claims to test:

1. "Retire within the next 4 years" — is the timeline right?
2. The 9-name basket — are they all the right names? Right category?

Where quantum actually is (2026 state)

Recent real milestones:

• Google Willow (Dec 2024) — first demonstration of quantum error correction below threshold (logical qubit error rate < physical qubit error rate). This was a structural milestone, not hype. Below-threshold means error correction can compound — every additional layer of redundancy reduces error rate, which makes large-scale fault-tolerance physically possible. Before Willow, this was an open question.
• IBM Heron r2 (2024-25) — ~156 qubits with significantly improved fidelity over Condor (1000+ qubits but noisy). IBM explicitly pivoted from qubit count to qubit quality circa 2024.
• Microsoft Majorana topological qubit announcement (Feb 2025) — contested by some physicists, but if validated, opens a separate hardware path with intrinsic error protection.
• AWS Ocelot (Feb 2025) — Amazon's first internally-built quantum chip targeting error-correction primitives.
• Anthropic/OpenAI/etc. exploring quantum-accelerated artificial-intelligence training (research-stage, no commercial impact yet).

What's NOT happening yet (2026):

• No commercially-useful "quantum advantage" in any economically-relevant problem (drug discovery, materials, finance, optimization). "Random circuit sampling" advantage demonstrated, but it's a benchmark not a use case.
• No fault-tolerant logical qubit operating in a useful algorithm. Willow demonstrated the primitive, not a running fault-tolerant computer.
• Pure-play quantum compute revenue is rounding error. IONQ ~$30-40M run-rate 2025, RGTI ~$10-15M, QBTS ~$8-10M. All burning cash, multi-year runway to profitability.

The mainstream-expert timeline (NOT @thestockwhale's "4 years"):

• 2025-2028: Quantum advantage demonstrations on toy problems → real problems (chemistry first, given Nature paper progress)
• 2028-2032: First fault-tolerant logical qubit demos in industrially-useful algorithms (drug discovery on small molecules, materials simulation)
• 2032+: Commercially-useful quantum computers running production algorithms. This is the "phase change."

McKinsey 2024 quantum-tech report puts the economic-value inflection in the 2030s, not 2028. Boston Consulting Group similar. Even quantum-bullish industry voices (Hartmut Neven, John Preskill) don't claim commercial fault-tolerance before late 2020s / early 2030s.

Verdict on the "retire in 4 years" claim: wrong on timing. The next 4 years (2026-2030) will see quantum advantage demonstrations on real problems and continued hardware milestones, but commercial scale value is later. Names that "let you retire in 4 years" would require a 10-20x bagger on a pure-play pre-revenue company, which depends on hyperscaler buyout / partnership announcements, not commercial revenue. The thesis is not analytically wrong about the long arc — quantum is real and economically significant — but wrong about the time-to-retire-on-it window.

The 9-name basket — first-principles audit

Categorizing by quantum-hardware-modality and revenue stage:

Real Phase-1 quantum-compute pure-plays (the actual thesis)

• IONQ (IonQ) ✅ — Trapped-ion. ~$30-40M revenue run-rate 2025. Hyperscaler integrations (AWS Braket, Azure Quantum, IBM Quantum). Multiple gov contracts (Air Force Research Lab). Most-commercialized of the pure-plays. Already in ai-scan.

• RGTI (Rigetti Computing) ✅ — Superconducting. ~$10-15M revenue. Earlier-stage than IONQ. Multi-chip module architecture is a credible long-term differentiator. Already in ai-scan.

• QBTS (D-Wave Quantum) ✅⚠️ — Annealing-based (NOT gate-based / fault-tolerant). Different technology entirely. Faster path to commercial use (~$10M revenue, real customers including Lockheed, Volkswagen, NASA) but capped ceiling — annealing doesn't generalize to all problems gate-based quantum can address. Worth coverage with the asterisk that QBTS is on a different long-arc trajectory than IONQ/RGTI/INFQ. Already filed for add per JFS basket.

• INFQ (Infleqtion) ✅ — Cold-atom / Rydberg-array quantum. Was ColdQuanta; SPAC merger with CF Acquisition VIII completed 2024. Public on NASDAQ. Real Phase-1 player with US Defense + Air Force funding ($3.5M ColdQuanta-original DoD contracts). Cold atoms is one of the credible long-arc paths (along with trapped-ion, superconducting, photonic). Genuine coverage gap.

• QUBT (Quantum Computing Inc) ⚠️ — Photonic quantum approach. Real ticker, real public company, but penny-stock volatility history + frequent pump-shape news cycles. Revenue ~$1M. Worth tracking but ranks below IONQ/RGTI/INFQ on conviction. Borderline add.

Diversified hyperscaler-class with quantum segments (much smaller of revenue)

• IBM (International Business Machines) ✅⚠️ — IBM Quantum is real (1000+ qubit Condor, Heron r2, quantum cloud services) but is rounding error of IBM total revenue. The "buy IBM for quantum" thesis is broken — you'd need IBM to spinoff its quantum business or do a major partnership disclosure for the quantum part of the story to move IBM's price meaningfully. Already in watching. Better quantum-via-mega-cap plays: GOOGL (Willow milestone) and MSFT (Majorana announcement) — neither is in the @thestockwhale list, both have more genuine quantum narrative leverage via concentrated bets.

Not actually quantum compute (category error)

• ARQQ (Arqit Quantum) ❌ — Post-quantum cryptography (PQC), NOT quantum compute. PQC = classical encryption algorithms designed to resist quantum-computer attacks. Different thesis entirely. Real federal regulatory tailwind (CNSA 2.0 transition through 2035) but Arqit specifically had a chequered history — SPAC pop / crash, SEC scrutiny on revenue recognition. PQC is a legitimate coverage gap as its own category; ARQQ is not the highest-conviction PQC name (alternatives: SQM, smaller-cap; or large-cap incumbents like Palo Alto Networks adding PQC offerings).

Recent 2026 SPAC IPOs — verified 2026-05-27

Both XNDU and HQ are real public tickers. The "probably private / phantom ticker" assessment in the original note was wrong — same internal-cross-note paraphrase-laundering failure as the INFQ error in 2026-05-26-merck-quantum-molecular-docking-verify-pass.md. Three quantum SPAC IPOs landed in early 2026:

• XNDU (Xanadu Quantum Technologies) — Toronto / Canadian, photonic quantum. Public via Crane Harbor Acquisition Corp SPAC; closing 2026-03-26, NASDAQ + TSX trading from 2026-03-27. $302M raise + up to CAD $390M Canadian/Ontario government funding for Project OPTIMISM (domestic quantum manufacturing). First publicly-listed photonic quantum company. Lockheed entities hold 2.3M shares (13G filed). Trading $17.27, market cap $4.72B as of 2026-05-26. Real Phase-1 photonic quantum play; legitimate coverage add.

• HQ (Horizon Quantum Holdings) — Singapore-HQ'd quantum software/IDE. IPO'd 2026-03-20, ~$120M gross proceeds. Product: Triple Alpha IDE for writing/compiling/deploying quantum software with hardware portability. Pre-revenue (Q1 2026 net loss $3.6M, zero revenue). Trading $12.09 as of 2026-05-26. Software-layer picks-and-shovels (different from hardware cohort); speculative, but real public name.

• INFQ (Infleqtion / formerly ColdQuanta) — also a 2026 SPAC IPO via Churchill Capital X, NYSE-listed Feb 2026. Already covered above; included here for cohort completeness.

Methodology correction — internal-cross-note paraphrase-laundering

The original "phantom ticker" call propagated a hunch about Xanadu/Horizon Quantum being private without a primary-source check on each ticker. The Motley Fool 2026-05-10 piece "3 Quantum Computing Stocks That Went Public in 2026 That You May Have Missed" surfaces these three names as a category — the SPAC IPO wave was widely covered. Lesson: internal note conclusions are not primary sources either — when one investigation says "verify needed," the next investigation cannot inherit that conclusion without re-verifying. [[capture-paraphrases-are-not-primary-sources]] applies to internal cross-references too, not just source-to-research.

The "two phantom-ticker pattern hits" framing was wrong. There were zero phantom tickers in this basket. Source-calibration accuracy revised below.

What we should actually be tracking for quantum (workspace-derived, not source-driven)

The pure-play hardware cohort (Phase 1 - 2026-2030 fundamentals):

• IONQ (trapped-ion, anchor)
• RGTI (superconducting, anchor)
• QBTS (annealing, different arc but real commercial use)
• INFQ (cold-atom, new add)
• QUBT (photonic, speculative, borderline add)

The hyperscaler quantum bets (narrative-leverage plays for mega-caps):

• GOOGL (Willow — best concentrated quantum narrative on a mega-cap; Sundar Pichai talks Willow on earnings)
• MSFT (Majorana topological)
• IBM (in watching already, but quantum is rounding error)
• AMZN (AWS Braket + Ocelot)

The picks-and-shovels enablers (the layer behind the layer):

• Cryogenics — superconducting qubits require ~10 mK dilution refrigerators. Bluefors (private) dominates. Public proxies: OXFORD INSTRUMENTS (OXIG.L) — already in trace-quantum-computing-physical-bottlenecks as OXINF (Oxford Instruments OTC ADR). Real bottleneck.
• Helium-3 supply — superconducting + dilution refrigerator essential input. Sourced mainly via tritium decay (DOE-controlled). No clean public play but worth tracking as a constraint.
• Ion-trap RF electronics — Honeywell Quantum (now spun into Quantinuum, private), some Keysight Technologies exposure.
• Photonic-qubit lasers — same supply chain as optical-supply-chain we already track (LITE, COHR for some wavelengths).

Post-quantum cryptography (PQC — different beat, real regulatory tailwind):

• ARQQ as listed (low conviction)
• Most legitimate PQC plays are inside larger cybersec companies (PANW / CRWD / FTNT, all already covered) or specialty IP-licensing (would need separate research)
• Federal CNSA 2.0 mandate runs through 2035

Coverage decisions

Per feedback_screener_dumps_bias_toward_adding_coverage_gaps.md — bias toward adding when thesis fit exists; per feedback_prove_dumb_or_validate_no_default_skip.md — validate or refute, don't dismiss.

High-conviction adds (4 names)

• QBTS (D-Wave Quantum) — already filed in JFS basket task. No new action; just confirms the add.
• INFQ (Infleqtion) — verified cold-atom Phase-1 player, post-SPAC, real DoD funding. Add to ai-scan AND a new dedicated quantum-compute watchlist (see below).
• GOOGL (quantum-narrative exposure) — already in mag7 / other watchlists. No new add needed; but Willow milestone should be noted on any quantum perspective when built.
• MSFT (Majorana exposure) — already in mag7. Same note as GOOGL.

Verify tasks (3 names)

• XNDU — verify if Xanadu is actually public. Likely phantom ticker.
• HQ — verify if Horizon Quantum is public. Likely phantom or different-company.
• QUBT — verify revenue base + recent SEC filings before borderline add.

Skip / wrong category (1 name)

• ARQQ — post-quantum cryptography, not quantum compute. Worth a separate post-quantum-cryptography decision if we want PQC coverage as a category, but ARQQ specifically is low-conviction (SPAC history + revenue-recognition issues). Don't add on this single source.

Structural decision — build a quantum-compute watchlist?

Currently quantum is split across ai-scan (IONQ/RGTI) + watching (IBM) + trace-quantum-computing-physical-bottlenecks (OXINF only). This is incoherent.

Recommended structure: build a dedicated quantum-compute.json watchlist:

• Phase-1 pure-plays: IONQ, RGTI, QBTS, INFQ
• Borderline: QUBT (after verify)
• Hyperscaler narrative-leverage (with weight-discount): GOOGL, MSFT, IBM, AMZN
• Picks-and-shovels: OXINF (Oxford Instruments — dilution refrigerators)

Total ~9 names, dedicated to the thesis. Don't bloat with PQC — that's a different beat. If we want PQC coverage, it gets its own watchlist later.

Overall verdict on the source thesis

• Long arc (quantum will matter): ✅ Real, structurally supported by recent milestones (Willow, Heron r2, Majorana).
• Time-to-retire framing ("4 years"): ❌ Wrong on timing. Commercial scale is 2030+, not 2028-2030. 4-year horizon picks pre-revenue names that depend on M&A / partnership catalysts, not fundamentals.
• Basket quality (revised 2026-05-27): 9/9 are real public tickers (zero phantoms — the original "2/9 phantom" call was wrong, see methodology correction above). 7/9 are on-thesis quantum compute plays (IONQ, IBM, INFQ, RGTI, QBTS, XNDU, HQ with HQ as software-layer pre-revenue). 1/9 is borderline by fundamentals (QUBT — real but penny-stock class with ~$1M revenue). 1/9 is wrong category (ARQQ = post-quantum cryptography, not quantum compute). Source-quality finding revised: ~78% on-thesis (7/9), 0% phantom-ticker rate, 11% wrong-category (1/9), 11% borderline-fundamentals (1/9). This is materially better than the original "55% / 22% phantom" assessment and roughly comparable to the asklivermore-network nuclear basket (89% / 5.6%). The vendor's quantum-ticker discovery was solid; the messenger is still skip-class on framing (paid-Discord-signal funnel + "retire in 4 years" pump shape), but the underlying basket warrants individual coverage decisions per the discovery-surface rule.

Action items

• Build stonks/watchlists/quantum-compute.json — 9-name dedicated watchlist per the proposed structure. Re-house IONQ + RGTI from ai-scan (keep in both via cross-reference). Add IBM (with quantum-is-rounding-error caveat in row note), GOOGL + MSFT + AMZN as narrative-leverage plays. Add INFQ (new). Cross-reference QBTS + OXINF.
• Watchlist add: INFQ (Infleqtion) — cold-atom Phase-1 play, post-SPAC, DoD funding base. Highest-conviction net-new add from this source.
• Verify: XNDU + HQ — RESOLVED 2026-05-27. Both are real 2026 SPAC IPOs. XNDU = Xanadu Quantum (NASDAQ + TSX, IPO 2026-03-27 via Crane Harbor, $302M + CAD $390M gov funding, $4.72B mkt cap, Lockheed 13G holder); HQ = Horizon Quantum Holdings (NASDAQ, IPO 2026-03-20, ~$120M raise, pre-revenue software/IDE). The "phantom ticker" call was internal paraphrase-laundering — corrections applied to body of note.
• Verify: QUBT revenue + SEC filings — borderline add pending substance check.
• Source-calibration log — CORRECTED 2026-05-27: thestockwhale 2026-05-25 quantum basket — 9/9 real tickers, 0% phantom, 78% on-thesis (7/9), 11% wrong-category (1/9 ARQQ), 11% borderline-fundamentals (1/9 QUBT). Original "55% / 22% phantom" assessment was wrong (internal paraphrase-laundering — see methodology correction above). Vendor's ticker discovery was solid; framing remains skip-class. Updated running source-quality table accordingly.
• Perspective consideration: is quantum-compute worth standing up as a perspective? Probably not yet — long-arc thesis with no near-term dated catalyst (compared to SpaceX IPO June 12 or China Ga/Ge/Sb expiry Nov 27). Build the watchlist first; revisit perspective after the next major milestone (next Google quantum disclosure, next IBM roadmap, next major hyperscaler partnership announcement) which would create a refresh trigger.

---

Update — 2026-07-01: Q4Bio Challenge data point (from the merck-quantum verify pass)

This block closes the follow-up filed by 2026-05-26-merck-quantum-molecular-docking-verify-pass (TASKS-RESEARCH.md). It propagates the April-2026 IBM Q4Bio Challenge milestone into this canonical first-principles note so the science/timeline anchor isn't orphaned in the sibling verify-pass note. All data is primary-sourced in the verify pass (IBM Newsroom 2026-04-16, IBM Quantum blog, MIT Tech Review 2026-03-19, HPCwire). No new fetch. No price claims in this update — tape truth for the pure-play cohort lives in the live quantum-computing perspective and research/market-engine/data/summaries/quantum-computing.json.

Four refinements to the "Where quantum actually is (2026 state)" and timeline sections above:

(a) New SOTA baseline: IBM Quantum Nighthawk, 120 qubits. Up from the ~96-logical-qubit framing implicit in early-2026 milestones (Willow / Heron r2). The $2M Q4Bio winner (Algorithmiq + Cleveland Clinic + IBM) ran circuits on up to 100 qubits at 1,000-10,000 gate depth on Nighthawk hardware. Use 120-qubit Nighthawk as the quarter-over-quarter benchmark for platform progress.

(b) First non-toy disease targets at the 100-qubit scale: PDT and DM1. Photodynamic therapy (light-activated cancer drugs; molecular electronic-structure simulation) was the $2M-winning application. Covalent drug-protein binding for myotonic dystrophy type 1 (DM1) was a named finalist (Nottingham). These are the first real-disease proof-of-concept targets quantum addressed at ~100 qubits — not commercial advantage, but the first step off pure benchmarks (random-circuit sampling). Note: no big pharma (Merck, Pfizer, Roche, AZ, GSK, Novartis, BMS, Amgen, Lilly) was in the finalist roster.

(c) The $5M Q4Bio grand prize was NOT awarded — this is the load-bearing datapoint. The grand prize required "a real-world healthcare problem on 100+ qubits that cannot be solved classically." It went unawarded in 2026; MIT Tech Review reported much of the prize money "may remain unawarded," and the program director publicly hedged: "It is very difficult to achieve something with a noisy quantum computer that a classical machine can't do." The absence confirms the 2028-2032 commercial-quantum-advantage floor holds for another year — the 2026 round produced publishable proof-of-concept, not classically-impossible results. (Calendar catalyst tracked separately: the ~April-2027 next cycle — TASKS-RESEARCH.md:365. If a team clears the 100+-qubit-classically-impossible bar in 2027, the floor shifts forward; a second no-award year extends it to ~2029-2033.)

(d) Hybrid quantum-classical workflows are the dominant near-term paradigm. Pure-quantum advantage on full molecular docking remains 2028+, but hybrid pipelines that use ~100 qubits to transform a classical ML step are showing publishable results now — e.g. the Merck KGaA + Amgen + Deloitte + QuEra Quantum Reservoir Computing work (clinical-trial-outcome prediction with small datasets, published in J. Chem. Inf. Model.). This is the shape of near-term "quantum in production," and it is not the molecular-docking story the original rumor claimed.

Per-ticker read (from the verify pass, carried forward)

Reconciliation with the live quantum-computing perspective (created 2026-06-30)

The perspective (post the 2026-06-22 executive orders + $2B sovereign-equity vehicle) frames the pure-plays as a "basket-first, lottery underneath" trade — policy/catalyst-driven, with pre-revenue equities unwinding a parabola. The unawarded Q4Bio grand prize is direct corroboration of the "lottery underneath" leg: no near-term classically-impossible quantum result means the pure-play upside stays dependent on M&A / policy / partnership catalysts, not commercial fundamentals — exactly the reason the perspective expresses the theme via ETFs (WQTM/CQTM) rather than single-name conviction. The Q4Bio hardware read (IBM ballast up, pure-plays not-yet-confirmed) is consistent with the perspective's "IBM/GOOGL = quality/catalyst ballast" framing.

Nothing here changes the coverage decisions already recorded above — this is a timeline/science-anchor refinement, not a new position.